Glorincor as a partner of Biocon biopharmaceutical company in Belarus is pleased to inform that Trastuzumab, a drug jointly developed by Biocon and Mylan, was approved in the Republic of Belarus on February 21 February 2019.
Biocon s Trastuzumab drug is registered in the United States and the European Union and has established itself as a highly effective drug.
Biocon's Trastuzumab is indicated for the treatment of patients with HER2-positive early breast cancer (EBC), metastatic breast cancer (MBC) and metastatic gastric cancer (MGC). Under the supervision of a qualified health care professional, it may be prescribed either as monotherapy or in combination with other medications depending
appropriate diagnosis.
Glorincor hopes to provide patients with access to its high Trastuzumab biosimilar to Herceptin®, which will be an important milestone for Glorincor, Biocon and the entire Belarusian healthcare system.